Spread the Word 📣

Exploring New Possibilities in Cell Preservation How can living cell therapies be stored and transported while maintaining their viability and function? This is one of the scientific challenges being addressed through the BioStabilization Systems (BoSS) program of the Advanced Research Projects Agency for Health (ARPA-H). CaseBioscience® is part of a multidisciplinary team led by Likarda that has been awarded up to $7.3 million to advance this work. Through the Reversible Ambient Biostabilization (RAB) project, the team aims to develop new approaches for storing and transporting living cellular medicines at ambient temperatures. CaseBioscience will contribute expertise in clinical media formulation, biopreservation, and cellular metabolism to this collaborative research effort. The long-term goal is to explore preservation approaches that could reduce dependence on cold-chain logistics and help address barriers to the distribution of advanced cell therapies. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

Reimagining how living cells are preserved. Cell therapies hold significant promise, but preserving and transporting living cells presents important scientific and logistical challenges. CaseBioscience® is selected to join a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by ARPA-H through its BioStabilization Systems (BoSS) program. Our contribution will focus on clinical media formulation, biopreservation, and cellular metabolism as the team explores new approaches to ambient preservation of cellular medicines. Scientific collaboration is helping drive the next generation of preservation research. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

Rethinking How Cell Therapies Are Preserved and Delivered Preserving the viability and function of therapeutic cells during storage and transportation remains an important scientific and logistical challenge for cell-based medicines. CaseBioscience® is proud to contribute to this effort as part of the Reversible Ambient Biostabilization (RAB) team, led by Likarda and awarded up to $7.3 million through the Advanced Research Projects Agency for Health (ARPA-H) BioStabilization Systems (BoSS) program. The initiative brings together multidisciplinary expertise to explore new strategies for the ambient storage and transport of living cellular medicines. CaseBioscience will contribute capabilities in clinical media formulation, biopreservation, and cellular metabolism to support the development and evaluation of novel cell-stabilization approaches. By bringing together complementary scientific and engineering expertise, the collaboration seeks to address longstanding challenges in biological preservation and cold-chain distribution. #CaseBioscience #ARPAH #Biopreservation

Advancing Cell Preservation Through Collaboration | CaseBioscience® How cells are preserved and transported is an important challenge in expanding access to advanced cell therapies. CaseBioscience® is contributing its expertise in clinical media formulation, biopreservation, and cellular metabolism to a multidisciplinary team led by Likarda, awarded up to $7.3 million by ARPA-H through its BioStabilization Systems (BoSS) program. The team aims to develop new approaches for preserving living cellular medicines at ambient temperatures, potentially reducing dependence on cold-chain logistics. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

CaseBioscience® Selected to Join ARPA-H-Funded Initiative to Advance Ambient Preservation of Cell Therapies CaseBioscience® is participating in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS) program. The team will pursue new approaches for preserving and transporting living cellular medicines at ambient temperatures, with the goal of reducing reliance on cold-chain logistics. CaseBioscience will contribute expertise in clinical media formulation, biopreservation, and cellular metabolism as part of this collaborative effort. Advances in cell preservation could help address logistical challenges associated with the distribution of cell therapies. The BoSS project brings together scientific and engineering expertise to explore new possibilities in this area. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

Advancing the future of cell preservation. CaseBioscience® has been selected to join a multidisciplinary team led by Likarda awarded up to $7.3 million by ARPA-H through its BioStabilization Systems (BoSS) program. The team’s Reversible Ambient Biostabilization (RAB) project aims to develop new approaches for preserving and transporting living cellular medicines at ambient temperatures. CaseBioscience will contribute expertise in clinical media formulation, biopreservation, and cellular metabolism to this collaborative research effort. Learn more about the project and our role in the full press release. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

CaseBioscience® selected to join a team led by Likarda awarded up to $7.3M by ARPA-H through its BoSS program to advance ambient preservation of cell therapies. CaseBioscience will contribute expertise in biopreservation, media formulation & cellular metabolism. #CaseBioscience #ARPAH #CellTherapy #Biopreservation

Reimagining how living cells are preserved. Cell therapies hold significant promise, but preserving and transporting living cells presents important scientific and logistical challenges. CaseBioscience® is selected to join a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by ARPA-H through its BioStabilization Systems (BoSS) program. Our contribution will focus on clinical media formulation, biopreservation, and cellular metabolism as the team explores new approaches to ambient preservation of cellular medicines. Scientific collaboration is helping drive the next generation of preservation research. #CaseBioscience #ARPAH #CellTherapy #Biopreservation